Skip to main content
Biotest AG logo

Biotest AG — Investor Relations & Filings

Ticker · BIO3 ISIN · DE0005227201 LEI · 529900JVX7RPXBLYUD89 F Manufacturing
Open in API
Filings indexed 1,148 across all filing types
Latest filing 2018-01-19 Director's Dealing
Country DE Germany
Listing F BIO3

About Biotest AG

https://www.biotest.com/de/en/index.cfm

Biotest AG is a global company that develops, manufactures, and supplies plasma protein products and biotherapeutic drugs. Sourced from human blood plasma, its products are primarily used in the therapeutic areas of clinical immunology, haematology, and intensive care medicine. The portfolio includes immunoglobulins (e.g., Intratect), coagulation factors, and albumins designed to treat severe and chronic diseases such as immune deficiencies, haemophilia, and coagulation disorders. The company manages the entire value chain from clinical development to sales and is advancing a pipeline of new treatments, including next-generation immunoglobulins (BT595) and fibrinogen concentrates (BT524). Biotest also provides Human Serum Albumin for use as a multifunctional excipient in pharmaceutical and diagnostic applications.

Recent filings

Filing Released Lang Actions
DGAP-DD: Biotest AG english
Director's Dealing Classification · 100% confidence The document is explicitly titled 'Directors’ Dealings' and contains a section titled 'Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them'. It details the name of a member of the managing body (Dr. Georg Floß), the nature of the transaction ('Disposal'), the price, volume, and date of the transaction involving company shares. This content directly matches the definition for Director's Dealing.
2018-01-19 English
DGAP-DD: Biotest AG english
Director's Dealing Classification · 100% confidence The document explicitly states 'Directors’ Dealings' at the top and uses the header 'DGAP-DD: Biotest AG english' which is a standard format for German Director's Dealings notifications (DGAP-DD). Section 4 details the 'transaction(s)' involving a 'Member of the managing body' (Dr. Michael Ramroth) and a 'Disposal' of shares. This directly corresponds to the definition of Director's Dealing.
2018-01-19 English
Biotest AG: All conditions met for Creat takeover of Biotest
M&A Activity Classification · 100% confidence The document is an 'Ad-hoc RELEASE' dated January 19, 2018, disclosing inside information according to Article 17 of the European Market Abuse Regulation (MAR). The core content announces that all conditions have been met for the takeover offer by Creat Group Corporation for Biotest AG, detailing the effective date and payment terms. This type of announcement, concerning a major corporate action like a takeover bid becoming effective, is a significant regulatory disclosure that doesn't fit neatly into standard financial reporting categories (like 10-K, IR, or ER). Since it is a specific, material corporate event announcement that is not a standard periodic report, and given the options, it best fits the general 'Regulatory Filings' category (RNS) as a catch-all for important, non-standard regulatory disclosures, or potentially 'TAR' (M&A Activity). However, 'TAR' is defined as 'Merger proposals or takeover bids.' This document confirms the *completion* and *effectiveness* of a previously announced takeover bid, which is a critical regulatory update. Given the strong focus on the takeover mechanism and its finalization, TAR is the most specific fit, although RNS is a possible fallback. I will classify it as TAR due to the explicit subject matter being a takeover.
2018-01-19 English
Declaration of Voting Results & Voting Rights Announcements 2018
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is explicitly titled 'Voting Rights Announcements' and contains sections detailing the 'Notification of Major Holdings' as per German Securities Trading Act (WpHG). It reports changes in voting rights percentages (crossing thresholds) held by a specific entity (J O Hambro Capital Management Limited) in Biotest AG. This directly corresponds to the definition of a Major Shareholding Notification.
2018-01-11 English
Biotest AG: Trimodulin: concept for phase III study successfully coordinated with the authorities
Legal Proceedings Report Classification · 99% confidence The document is a 'News Details' release dated December 20, 2017, originating from Biotest AG, disseminated via DGAP-News. The content focuses on a research update regarding the drug Trimodulin, specifically coordinating the concept for a Phase III study with regulatory authorities. It discusses clinical development, regulatory support, and optimization of the production process. This type of announcement, detailing progress in clinical trials and regulatory interactions, is not a formal financial report (like 10-K or IR) nor a standard earnings release (ER). It is an update on research and development activities. Since it is a specific announcement about clinical/research progress that doesn't fit the other specific categories (like M&A, Capital Change, Dividend), it falls best under the general 'Regulatory Filings' (RNS) category as a corporate news item disseminated through regulatory channels, or potentially a specialized research update if one existed. Given the provided definitions, 'RNS' (Regulatory Filings - general regulatory announcements and fallback) is the most appropriate fit for a press release detailing regulatory coordination on a drug study, especially since it is not a formal financial report or a management/board change announcement.
2017-12-20 English
Report Publication Announcement 2017
Report Publication Announcement Classification · 100% confidence The document is titled 'Preliminary announcement of the publication of quarterly reports and quarterly/interim statements' and explicitly states that it is announcing *when* future financial reports (Q1 and Q3 reports for 2018) will be disclosed, providing dates and links to where they will be published. This is not the report itself (like an IR or 10-K), but an announcement about the publication schedule of those reports. According to Rule 2 (The 'MENU VS MEAL' Rule), a short announcement stating that a report 'has been published' or will be published fits the description of a Report Publication Announcement (RPA).
2017-12-06 English

Browse filings by year

29 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.